Angiotensin ii
As of the edition of 20 October 2026, Angiotensin ii is a protein: marketed, first approved in 2017 (US); acts on AGTR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Protein
- Brand name
- Giapreza
- First approved
- 21 December 2017 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- L; 2 holders in all
- Registered trials
- 36, 6 stopped early
- Disease areas
- Infections; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Digestive system; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Angiotensin ii.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 3 | 1 | 3 |
| Phase 1 | 5 | 2 | 2 | 1 |
| Phase 2 | 4 | 1 | 1 | 1 |
| Phase 3 | 6 | 2 | 3 | 0 |
| Phase 4 | 12 | 4 | 6 | 1 |
| All trials | 36 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| L | Originator and Lead sponsor of trials | 2017 to now |
| PAION Pharma | Applicant | 2019 to now |